Understanding Personality Styles of Women in Phase Ii and Iii Rheumatoid Arthritis Clinical Trials by Riccardi, Elisabeth Ann
  
 
 
 
UNDERSTANDING PERSONALITY STYLES OF WOMEN  
 
IN PHASE II AND III RHEUMATOID ARTHRITIS  
 
CLINICAL TRIALS  
 
 
 
 
 
 
 
 
By 
 
ELISABETH ANN RICCARDI 
 
 
Bachelor of Arts 
 
The University of Oklahoma 
 
Norman, Oklahoma 
 
2002 
 
 
 
 
 
 
Submitted to the Faculty of the 
Graduate College of the 
Oklahoma State University 
in partial fulfillment of  
the requirements for 
the Degree of 
DOCTOR OF PHILOSOPHY 
December 2008 
  
ii
 
 
 
 
 
 
 
UNDERSTANDING PERSONALITY STYLES OF WOMEN  
 
IN PHASE II AND III RHEUMATOID ARTHRITIS  
 
CLINICAL TRIALS  
 
 
 
 
 
 
     Dissertation Approved: 
 
 
        Dr. Don Boswell 
Dissertation Approved________________________________________  
        Dissertation Advisor 
 
         Dr. Dale Fuqua 
Dissertation Approved________________________________________ 
                                                               Committee Member 
  
                                                               Dr. Steve Harrist 
Dissertation Approved ________________________________________ 
                                                               Committee Member 
 
                                                               Dr. Julie Dorton 
Dissertation Approved ________________________________________ 
                                                               Committee Member 
 
                                                           Dr. A. Gordon Emslie 
Dissertation Approved ________________________________________ 
                                                         Dean of the Graduate College 
  
  
iii 
ACKNOWLEDGEMENTS 
 
 
 This has been the page I most look forward to writing, as it means I have come to 
the end of this long journey.  First I want to thank Phyllis Morris and the rest of the staff 
at Healthcare Research Consultants who diligently aided in the data collection process.  I 
would also like to thank Dr. William Surbeck and his nurse, Linda Seacrest for allowing 
me to collect data at their busy office.  There is no question this could not have happened 
without your time and effort. 
 I most definitely have to thank my Advisor, Dr. Don Boswell, and the rest of my 
committee, Dr. Steve Harrist, Dr. Julie Dorton, and Dr. Dale Fuqua.  You held my hand 
and led me through this and most of all helped me to see the light at the end of the tunnel.  
And it was a long, long tunnel.  My parents were there from the moment I said I wanted 
to enter the program, until the end, and provided the appropriate “gentle” encouragement 
I needed to get my work done.  My sister, Melissa Farris, gets a special thank you for 
making what seemed like a million copies of assessments for me and being my courier.  
And last, I want to thank my husband, Todd Vining, for also “gently” encouraging me to 
finish, for his unending support, and for his divine excel skills.  You all are the best! 
  
iv
TABLE OF CONTENTS 
 
Section          Page 
   
INTRODUCTION………………………………...………………………………………1 
 
METHOD…………………………………………………………………………..……..5 
    Participants………………………………………………………………………5 
    Procedure……………………………………………………………….……….6 
    Instrument…………………………………………………………………….…7 
       
RESULTS………………………………………………………………………………..11 
Demographic Comparison of Groups…………………………………………11 
Analyses of Personality Differences…………………………………………..13 
 
DISCUSSION……………………………………………………………………………18 
 
BIBLIOGRAPHY………………………………………………………………………..22 
 
APPENDICES…………………………………………………………………………...24         
APPENDIX A- Review of the Literature…………….……………………….....26 
Clinical Trials………………………………………………………………….26 
 What is a Clinical Trial………...………………………………………...26 
        Who are the Volunteers….………………………………………………28 
 Potential Risks and Benefits……………………………………………..30 
 Why Volunteer…………………………………………………………...32 
 Personality and Clinical Trials…………………………………………...34 
 The Future of Clinical Research…………………………………………36 
Rheumatoid Arthritis………………………………………………………….38 
       What is Rheumatoid Arthritis…………………………………………….38 
 Personality and Rheumatoid Arthritis……………………………………39 
 Personality and the Course of Illness…………………………………….45 
            Clinical Trials and Rheumatoid Arthritis……………………………………...49 
            Literature Review Bibliography………………...…………………………….53        
APPENDIX B- Demographic Questionnaire….…………………………………57        
APPENDIX C- Informed Consent…………………………………………….…58        
APPENDIX D- Solicitation Script…………………………………………….…59       
APPENDIX E- Institutional Review Board Consent …….………………….…..60 
        
  
  
v
LIST OF TABLES 
 
 
Table               Page 
 
1.   Frequency Chart of Demographic Variables Between Groups ….…………………..12 
2.  Results for MIPS-R: Means and Standard Deviations……………….....…………….15 
3.  MANOVA Results for MIPS-R Between Groups……….………….…….………….15 
 
 
 
 
 
 
LIST OF FIGURES 
 
 
 
Figure             Page 
 
1. Summary of MIPS-R Results Between Groups……………….………………………16 
 
2. Mean Prevalence Scores on MIPS-R…..……………………….……………………..17 
 
  
1
INTRODUCTION 
 
Before any medication can be distributed, it must first undergo a series of four 
extensive clinical trials on human subjects to ensure the safety and efficacy of the drug, 
as outlined by the Food and Drug Administration (CFR, Section 21).  These trials range 
from small studies conducted on seemingly healthy, asymptomatic volunteers called 
Phase I trials, to smaller trials testing safety and efficacy in symptomatic participants 
known as Phase II and III trials, to mass post-market studies conducted on thousands of 
symptomatic participants, or Phase IV trials (“An Introduction to Clinical Trials,” 2006).  
There is a large body of research looking at why people choose to participate in Phase I 
trials where healthy volunteers are used to assess safety of the drug by introducing the 
drug to the human body (Lowton, 2005; Meyer, 2001; Harth, Johnstone, Thong, 1992).  
Identified factors influencing participation include financial compensation, altruism, 
promotion of science, and personality traits such as extroversion, low anxiety, 
independence, and openness to new experiences (Lowton, 2005, Weinfurt, K.P., et al, 
2003; Crumbo, C.L., Rybeczyk, G.K., Wagner, L.J., 1997).   However, there is limited 
research on how these factors influence volunteer participation in latter phases of clinical 
research when the drug is tested on symptomatic participants, or patients who possess the 
medical condition the drug is intended to treat.   
Given the research collected on phase I participants, one may guess that factors 
such as financial incentives and free healthcare play a role in one’s decision to participate 
in a Phase II or III clinical trial as well (Lowton, 2005).  One may also guess that 
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personality is an influencing factor for participation as it is in phase I.  However, 
personality traits identified in phase I participants such as openness to new experiences, 
low anxiety, independence, and extroversion are not commonly seen in people with long 
term chronic illnesses such as rheumatoid arthritis, cystic fibrosis, and heart disease 
(Lowton, 2005, Came, J. et al., 1989; Moos and Solomon, 1965).  Numerous studies have 
repeatedly found depression, high anxiety, introversion, and hopelessness associated with 
chronic illness (Bauer, H., and Duijsens, I.J., 1998; Ashutosh, et al., 1997).  Given the 
obvious discrepancy of the identified personality characteristics typically seen in clinical 
trial volunteers and those reportedly seen in chronically ill patients, there appears to be a 
need to identify if there are personality characteristics specific to chronically ill patients 
who choose to participate in clinical trials.  This study will focus specifically on patients 
with Rheumatoid Arthritis (RA) and if personality characteristics seen in phase I 
volunteers are also found in phase II and III pharmaceutical trials as well.   
Nearly 40 million Americans have been diagnosed with some form of arthritis, 
making it the leading cause of disability in the Unites States, with prevalence and 
incidence rates two to three times higher in females than in males (Mayo Clinic, 2002).  
Rheumatoid arthritis was chosen for this study not only because of the high prevalence 
rates and attention it has received in the pharmaceutical world, but also because of the 
significant amount of research that has been dedicated to the study of personality styles of 
those who have been diagnosed with the illness.  There have been many well-established 
links between personality and the onset and course of rheumatoid arthritis (Moos and 
Solomon, 1965).  An early study comparing arthritic women to non-arthritic siblings 
found that overall the arthritic participants showed more subservience, nervousness, 
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restlessness, depression, conservatism, and hypersensitivity to anger, which later research 
was able to link to a positive or negative course of illness (Moos and Solomon, 1963; 
Moos, et al, 1963, 1965).  However, it is not clear if personality traits associated with the 
illness were present before the illness, or if they are the result of a very painful and 
disabling chronic illness. 
Research also suggests that personality is linked to level of functioning; 
participants who exhibit poorer functioning display greater introversion, depression, 
social isolation, anxiety, anger, fear, and insufficient coping skills, while higher 
functioning individuals displayed more extroversion, greater coping skills, etc.  And 
while there is some disagreement about the exact role personality and psychosocial 
factors play in disease development, most agree that it can have an impact on the efficacy 
of treatment, including one’s response to medication (Meyer, 2001).  This fact 
necessitates the need for the pharmaceutical companies to understand the type of person 
participating in clinical studies, as personality may impact the efficacy results and 
generalizability of new medications.   
As previously stated, research conducted on phase I participants reveals an 
openness to new experiences, low anxiety, sociability, and independence (Lowton, 2005, 
Weinfurt, K.P., et al, 2003; Crumbo, C.L., Rybeczyk, G.K., Wagner, L.J., 1997).   The 
present study looked to determine whether rheumatic clinical trial participants possessed 
similar personality styles to phase I participants, or if they displayed styles consistent 
with those of the rheumatic population.  The hypothesis was that participants in the phase 
II and III trials displayed personality styles more consistent with those of phase I 
volunteers versus those of the chronically ill.  Specifically, the researcher expected the 
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clinical trial participants to display higher levels of extroversion, independence, 
willingness to take risks, and lower anxiety than patients with Rheumatoid Arthritis that 
are not in trials.  This study attempted to answer that question by comparing the results of 
a personality assessment taken by arthritic patients who are currently or have previously 
been enrolled in a pharmaceutical drug trial and arthritic patients who have not.   
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METHOD 
Participants 
Data were collected from two groups of participants.  Both the experimental and 
the control groups consisted of female participants between the ages of 23-83 who were 
diagnosed as “definite” or “classical” Rheumatoid Arthritis, as defined by the ARA 
Diagnostic Criteria for rheumatoid arthritis (Arnett, Et al., 1988).  To meet criteria for 
definite RA, participants must experience four to five of the following symptoms: 
morning stiffness, arthritis of three or more joint areas, arthritis of hand joints, 
symmetrical soft tissue joint swelling, subcutaneous rheumatoid nodules, radiographic 
changes, or a positive serum rheumatoid factor.  For a classical diagnosis participants 
must meet six to seven of these criteria.  The participants fit within classes II and III of 
the global functioning status as defined by the American College of Rheumatology 
(Hochberg, et al., 1992).  Those classes are broken into four divisions: class 1- no 
functional impairment in daily living tasks; class 2- able to adequately function in normal 
life with minor impairment; class 3- limited function, but still able to engage in daily 
living tasks; class 4- unable to function independently.   
Women only were selected for this current study due to the higher prevalence of 
rheumatoid arthritis in women versus men.  Limiting the study to women only also 
helped control for personality differences that may be better attributed to gender 
differences.  The experimental group or Clinical Trial Participant group (referred to as 
“CT-Participant” from this point forward) consisted of forty-four female participants who 
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were enrolled in a Phase II or Phase III Rheumatoid Arthritis pharmaceutical drug trial at 
the time of the study.  The number of participants was limited by the size of the 
pharmaceutical research facility.  Participants were recruited through an independent 
pharmaceutical research facility in the Midwest.  The control group, or Non-Clinical Trial 
Participant group (referred to as “NCT-Participants” from this point forward) consisted of 
thirty-eight females who had never participated in a clinical trial for rheumatoid arthritis 
or any other illness/condition.  These patients were recruited through physicians’ offices 
that specialize in the treatment of RA. Approval was obtained from the Institutional 
Review Board at Oklahoma State University. 
Procedure 
Prior to the beginning of the study, packets were distributed to the participating 
physician’s office and research facility, which then gave them to consenting participants.  
Included in these packets were an informed consent (see Appendix C), a demographic 
questionnaire (Appendix B), and the Millon Inventory of Personality Styles Revised 
(MIPS-R), a paper and pencil personality inventory.  The packets were prepared with a 
counter-balance of presentation of the demographic survey and assessment to protect 
internal validity.  Once the information was filled out, participants sealed their envelopes 
and return them to the physician’s staff.  The researcher collected the packets from each 
facility on a weekly basis until data collection was complete.  To protect confidentiality, 
each participant’s identifying information was collected separately from the assessment 
materials.  Specifically, participant consent forms were collected in a single envelope that 
remained separate from each sealed envelope containing the completed demographic 
questionnaire and MIPS assessment.   Participants had the opportunity to enter their name 
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separately for one of four twenty-five dollar drawings.  A separate form was available in 
the assessment packet, which allowed participants to enter their name and phone 
number/email address.  These forms were also stored in a separate envelope from the 
demographic questionnaire and MIPS so as to protect participant confidentiality.   
All participants were asked to complete a demographic questionnaire that 
assessed variables including age, income, education, ethnicity, access to health insurance, 
access to Medicaid/Medicare, and motivation for their participation in the current or 
previous clinical trial if applicable (see Appendix B).  Specified motives for participation 
assessed in previous research included the following: financial incentives (including 
compensation, free healthcare, and free medication), dedication to the advancement of 
science, physician recommendation, and altruism (Lowton, 2005, Weinfurt, K.P., et al, 
2003; Crumbo, C.L., Rybeczyk, G.K., Wagner, L.J., 1997).  Information was obtained on 
socioeconomic status and level of education as these variables have been linked to the 
onset and progression of rheumatoid arthritis as well as motivation for participating in 
clinical research (Harth, et al., 1992). 
Instrument 
Each participant completed the Millon Personality Style Index-Revised (MIPS-
R), a non-clinical one hundred and eighty-item true/false assessment of general 
personality traits.  Developed by Theodore Millon (2004), the MIPS-R measures twenty-
four personality styles or traits through twelve pairs of bipolar content scales.  These 
include six Motivating Styles (pleasure-enhancing vs. pain-avoiding, actively modifying 
vs. passively accommodating, and self-indulging vs. other-nurturing), eight Thinking 
Styles (externally focused vs. internally focused, realistic/sensing vs. imaginative/ 
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intuiting, thought-guided vs. feeling-guided, and conservation-seeking vs. innovation-
seeking), and ten Behaving Styles (asocial/withdrawing vs. gregarious/ outgoing, 
anxious/hesitating vs. confident/asserting, unconventional/dissenting vs. 
dutiful/conforming, submissive/yielding vs. dominant/controlling, and dissatisfied/ 
complaining vs. cooperative/agreeing).  There are three validity indices: positive 
impression, negative impression, and consistency.  The assessment was designed at an 
eighth grade reading level and can be administered through paper and pencil or online.  It 
takes an estimated twenty to thirty minutes to complete.  Because prior research and 
related literature identifies personality traits such as extroversion, anxiety, independence, 
and risk taking as prevalent among phase I participants, this study focused on four sets of 
polar scales for a total of eight scales in the MIPS-R that reflect those styles.  Specific 
scales that identify personality issues of extroversion, anxiety, independence, and risk 
taking are the externally focused vs. internally focused scales, conservation-seeking vs. 
innovation-seeking scales, anxious/hesitating vs. confident/asserting scales, and the 
submissive/yielding vs. dominant/controlling scales.  Breaking each scale down further, 
the elevated scores on the externally focused scale suggests a pattern of turning to others 
for stimulation and support.  It suggests a dependence on others for guidance and feelings 
of self-worth.  Elevated scores on the internally focused scale suggest drawing from her 
own feelings for inspiration, at times resulting in a distancing from others.  An elevated 
score on the Conservation-Seeking scale suggests a trend towards orderliness, 
traditionalism, and conservative behavior and beliefs.  This scale is counterbalanced by 
the Innovation-Seeking scale, suggesting a tendency towards risk-taking and creativity.  
The Anxious/Hesitating scale measures tendencies towards shyness, timidity, and 
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anxiety, while the Confident/Asserting scale measures outspokenness, ambitiousness, and 
self-assuredness.  An elevated score on the Submissive/Yielding scale indicates a 
tendency towards suffering and domination, possibly giving up opportunities to help 
themselves while waiting for others to help.  The Dominant/Controlling scale suggests 
domineering behavior, fearlessness, and aggression.    
The MIPS-R utilizes prevalence scores ranging from zero to one hundred instead 
of standard T-scores, with a reference score of fifty indicating possession of that 
personality style.  Scores were standardized on four samples: adult men and women and 
college-age men and women.  Separate gender norms are used when determining the 
prevalence scores.  Median reliability coefficients for the adult male and female samples 
are .76 and .78 respectively, with a median split-half reliability of .80 for both males and 
females (Millon, 2004). Given the participant sample in the current study, only statistical 
data for the female adult population was used.  For the scales used in the current study 
coefficient alpha ranged from .71 (Innovation-Seeking) to .85 (Anxious/ Hesitating).  
Test-retest data showed a .85 median correlation coefficient in a study of fifty adults who 
took the test twice in a range of 20-82 days.  Test retest reliabilities for the scales used in 
the current study range from .83 (Conservation-Seeking) to .90 (Externally Focused, 
Internally Focused, Innovation-Seeking, and Submissive/Yielding).  Strong patterns of 
scale inter-correlations and  scale-item overlap also suggest moderately strong internal 
validity.  
The MIPS-R correlates positively with several established personality 
assessments including the Myers Briggs Type Indicator (MBTI), 16PF, California 
Psychological Inventory, NEO Personality Inventory, and the Minnesota Multiphasic 
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Personality Inventory-2 (MMPI-2) (Millon, 2004), indicating strong external validity.  
For example, the Externally Focused scale of the MIPS-R correlates inversely with the 
Enthusiastic (r =. 61) and the Bold (r = .72) traits measured by the 16PF.  The Bold trait 
also correlated with the Confident/Asserting scale (r = .70) and the Anxious/Hesitating 
scale (r = -.72).  The Extraversion factor measured in the 16PF correlates with the 
Externally Focused (r = .75) and the Anxious/Hesitating (r = -.62) scales.  The Anxiety 
Factor of the 16PF correlates with the Anxious/Hesitating scale (r =.50).  The 
Independence factor of the 16PF moderately correlates with the Confident/Asserting 
scale (r =.54).   The Externally Focused scale correlates most strongly with the 
Extraversion and Introversion scales of the MBTI (r =.67 and -.71 respectively), as does 
the Internally Focused scale (r =-.63 and r =.64 respectively).  The Anxious/Hesitating   
(r =-.55 and r =.60) and Confident/Asserting (r =.46 and r =-.52) scales also correlate 
most strongly with the Extroversion and Introversion scales of the MBTI.  The 
Conservation-Seeking scale correlates with the Judging and Perceiving scales of the 
MBTI (r =.59 and -.60 respectively).  The Innovation-Seeking scale also correlates most 
strongly with the MBTI Judging and Perceiving scales (r =-.51 and .55 respectively).   
The MIPS-R was selected for several reasons, the most important being its ability 
to provide a solid yet broad assessment of personality traits found in a normal population 
sample.  The specific content scales allowed for the measurement of identified factors 
including anxiety and dependence previously identified as traits found in arthritic 
patients, while scales such as innovation-seeking would suggest the openness to new 
experiences commonly seen in clinical trial participants.  While other assessments such 
as the 16PF and NEO-PI would provide similar information, this particular assessment is 
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shorter in length and simplified in its True/False answering style, which may have been 
easier for patients to complete given the possibility of joint pain and physical discomfort 
often seen in arthritic patients.    
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RESULTS 
Given the hypothesis that there would be significant differences between the CT-
Participant and the NCT- Participant groups on scales reflecting extroversion (scales 4A-
Externally Focused and 4B-Internally Focused), openness to new experiences (scales 7A- 
Conservation-Seeking and 7B-Innovation-Seeking), independence (scales 11A-
Submissive/Yielding and 11B-Dominant/Controlling), and anxiety (scales 9A-
Anxious/Hesitating and 9B—Confident/Asserting), the best approach was to conduct a 
series of four MANOVAs with follow-up ANOVAs if the MANOVA was significant.  
This allowed for the greatest measurement of difference between groups, while providing 
protection against Type I error. 
The data analyses also included comparisons between the participant and non-
participant groups on demographic variables including Age, Level of Education, 
Household Income, Access to Health Insurance, and Access to Medicaid/Medicaid, 
through the use of multiple one-way ANOVAs and chi-square analyses. 
Demographic Comparison of Groups 
Data were collected from eighty-two female participants over the course of two 
months (n=44 for CT-Participants; n=38 for NCT-Participants).  The ages ranged from 23 
years to 83 years old, with a mean age of 56.68 years (mean = 54.55, SD 10.877 for CT-
Participants; mean = 59.16, SD 14.181 for NCT-Participants). See Table 1 for complete 
frequency response information on demographic variables. 
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Table 1: Frequency Chart of Demographic Variables Between Groups 
                                          CT-Participants          NCT-Participants 
Household Income                           No Answer 
                                                         Under $15000 
                                                         $15000-$30000 
                                                         $30000-$45000 
                                                         $45000-$60000 
                                                         $60000 + 
1 
6 
10 
9 
8 
10 
6 
2 
5 
4 
7 
14 
Level of Education            Did not complete H.S 
                                           High School/GED 
                                           Some College/Technical 
                                           College/Technical Degree 
                                           Graduate School 
7 
10 
8 
13 
6 
3 
12 
8 
11 
4 
Race/Ethnicity                           Caucasian 
                                                   African American 
                                                   Hispanic/Latino 
                                                   Native American  
35 
1 
1 
7 
32 
1 
0 
7 
Heath Insurance                                   Yes 
                                                              No 
36 
8 
37 
1 
Currently Employed                            Yes 
                                                              No 
23 
21 
15 
23 
Receiving Medicaid/Medicare            Yes 
                                                             No 
17 
27 
14 
24 
Participant in Previous Trial                Yes 
                                                              No 
3 
 41 
0 
38 
 
Several one-way ANOVAs were conducted on demographic variables including 
age, income, and level of education.  At alpha< .05, no significant differences were found 
between groups on any of these variables (Age-F(1,81)=2.770, p=.100; Household 
Income-F(1,81)=.151, p=.699; Level of Education-F(1,81)=.000, p=.990).  No inferential 
statistics were conducted for the demographic variable, ethnicity. It can be seen, however, 
from a visual inspection of the data that the grand majority of the participants in the both 
groups were Caucasian. Of significant note is that there were seven Native Americans in 
both the CT-Participant group and NCT-Participant group.  Chi-square analyses were 
conducted on variables that yielded a Yes/No response including current employment, 
previous participation in a clinical trial and access to health insurance and 
Medicaid/Medicare.  A significant difference was found in access to health insurance 
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(Pearson Chi-Square with one degree of freedom=5.05, p=.025). No significant 
differences were found in current employment (Pearson Chi-Square with one degree of 
freedom=1.343, p=.246), Medicaid/Medicare (Pearson Chi-Square with one degree of 
freedom= .028, p=.867), and previous enrollment in a clinical trial (Pearson Chi-Square 
with one degree of freedom=2.689, p=.101). 
The mean scores of reasons to participate in clinical trials were also calculated 
from data collected from the CT-Participant group, including Free Healthcare/ 
Medication, To Help Others, To Improve Science, Financial Compensation, Doctor 
Recommendation, and Previous Treatment Was Not Effective.  Only CT-Participants 
were asked to rank on a scale of one (strongly disagree) to five (strongly agree) the 
influence these factors had on the decision to participate in a clinical trial.  The results 
were as follows: To Help Others (mean=3.39; SD=1.833), To Improve Science 
(mean=3.34; SD= 1.855), Free Healthcare (mean=2.93; SD=1.676), Financial 
Compensation (mean=1.82; SD=1.317), Doctor Recommendation (mean=3.50; 
SD=2.029), and Previously Ineffective Treatment (Mean=3.09; SD=1.939). 
Analyses of Personality Differences 
Because the MIPS-R uses prevalence scores instead of T-scores or stanines, the 
results did not provide normative data so all analyses were conducted using the raw 
scores (See Figure 1 for a graphic representation of the means for each group).   
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Fig 1.  Summary of mean raw scores on MIPS-R scales between CT-Participant and NCT- Participant    
           groups. 
 
 
 
 
 
 
 
Table 2: MIPS-R Raw Score Means and Standard Deviations 
Group External 
Focused 
Internal 
Focused 
Conser. 
Seeking 
 
Innov. 
Seeking 
Anxious 
Hesitate 
Confident 
Asserting 
Submis. 
Yielding 
Dominant 
Control. 
CT-Part.                 
 
Mean                 
 
Std. 
Deviation 
 
 
25.75 
 
9.224 
 
 
11.55 
 
7.822 
 
 
35.59 
 
9.968 
 
 
23.34 
 
9.899 
 
 
15.95 
 
11.475 
 
 
28.98 
 
10.832 
 
 
16.89 
 
6.085 
 
 
15.23 
 
7.291 
NCT-Part.              
 
Mean 
                             
Std. 
Deviation 
 
 
29.34 
 
10.278 
 
 
9.95 
 
8.504 
 
 
42.45 
 
10.428 
 
 
21.92 
 
8.152 
 
 
12.50 
 
12.390 
 
 
32.58 
 
12.185 
 
 
15.16 
 
8.096 
 
 
16.03 
 
7.038 
 
Four separate MANOVAs were conducted comparing the results of the eight 
MIPS-R scales between the CT-Participant and NCT-Participant groups (see Tables 2-4).  
Each MANOVA compared two polar scales; for example the first MANOVA compared 
scores on the Introversion scale and scores on the Extroversion scale between groups.  If 
any significant differences were found at the p<.05 level, univariate follow-up ANOVAs 
were performed to confirm a significant difference on that scale. 
Specifically the first MANOVA analyzed the results of the Introversion and 
Extroversion scales between the two groups (see Table 3).  No significant results were 
0
5
10
15
20
25
30
35
40
45
CT-Participants NCT-Participants
CT-Participants 25.75 11.55 35.59 23.34 15.95 28.98 16.89 15.23
NCT-Participants 29.34 9.95 42.45 21.92 12.5 32.58 15.16 16.03
Externally
Focused
Internally 
Focused
Conservation-
Seeking
Innovation-
Seeking
Anxious/
Hesitating
Confident/
Asserting
Submissive/
Yielding
Dominant/
Controlling
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found (F (2,79)= 1.986; p=.144).  The second MANOVA compared the Conservation-
Seeking and Innovation-Seeking subscales.  A significant difference was found at the 
p<.05 level (F (2,79)=4.571; p=.013). Follow-up ANOVAs confirmed a significant 
difference (F(1,80) = 4.612, p=.013) on the Conservation-Seeking scale, but no 
difference on the Innovation Seeking Scale (F(1,80)=.493, p=.485). The third MANOVA 
compared scores on the Anxious/Hesitating and Confident/Asserting scales.  No 
significant differences were found at the p<.05 level (F (2,79)=1.058; p=.352)  The final 
MANOVA compared the Submissive/Yielding and the Dominant/Controlling scores 
between groups.  No significant differences were found at the p<.05 level (F (2,79)=.607; 
p=.548). 
Table 3: MANOVA Results  
GROUP Wilkes 
Lambda 
Value 
F Hypothesis 
df 
Error 
df 
Sig 
MANOVA 1 
Externally Focused/ 
Internally Focused 
.952 1.986 2.000 79.000 .144 
MANOVA 2 
Conservation-Seeking/ 
Innovation-Seeking 
.896 4.571 2.000 79.000 .013 
MANOVA 3 
Anxious/ Hesitating 
Confident/Asserting 
.974 1.058 2.000 79.000 .352 
MANOVA 4 
Submissive/Yielding 
Dominant/ Controlling 
.985 .607 2.000 79.000 .548 
 
 
The mean raw scores for each scale were then computed into a mean prevalence 
score in order to provide insight into the response patterns of each group (see Figure 2).  
The prevalence scores fell on a scale of zero to one hundred, with zero being low and one 
hundred being high.  Any score higher than fifty recognizes a presence of that personality 
style.  Results from the CT-Participant group ranged from 31 on the Dominant-
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Controlling scale to 48 on the Conservation-Seeking group.  Though the CT-Participant 
group scored significantly lower on the Conservation Seeking scale, the score still fell 
within the average range (prevalence score=48).  The NCT-Participant group’s 
prevalence scores ranged from 27 on the Innovation-Seeking scale to 64 on the 
Conservation-Seeking scale.  They had three scores above 50: the Externally Focused, 
Conservation-Seeking, and the Confident/Asserting, indicating a presence of those 
personality styles. 
 
Figure II: Prevalence score determined by mean raw score for both NCT-Participant and CT-Participant  
                 Groups on 8 MIPS-R Scales 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Externally 45 46 Internally
Focused 58 43 Focused
Conservation- 48 32 Innovation-
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DISCUSSION 
It was hypothesized that Clinical Trial Participants would possess personality 
characteristics reportedly seen in Phase I clinical trial volunteers, such as openness to 
new experiences, low anxiety, independence, and extroversion (Lowton, 2005, Weinfurt, 
K.P., et al, 2003; Crumbo, C.L., Rybeczyk, G.K., Wagner, L.J., 1997).  These traits differ 
significantly from those seen in personality research in rheumatic patients, which 
includes higher levels of dependence, anxiety, and introversion (Lowton, 2005; Cami, J. 
et al.; 1989; Moos and Solomon, 1965).  These apparent differences in personality styles 
in populations that overlap in the clinical research field, and the lack of documented 
research on those differences, are what led to the current study. This study sought to 
determine if there are underlying personality characteristics that differentiate people with 
rheumatoid arthritis who participate in clinical trials, from those who do not.  This 
knowledge could possibly lead to a greater understanding of what the clinical trial 
participant looks like in Phase II and III studies, thus aiding in the efficacy and 
generalizability of pharmaceutical research as well as recruitment and retention for 
pharmaceutical trials.    
To test the hypothesis that there are personality differences between RA patients 
who participate in clinical trials versus those who do not, eighty-two women diagnosed 
with RA were given a demographic questionnaire and general personality assessment, the 
Millon Index of Personality Styles- Revised (MIPS-R) (Clinical Trial Participants N=44; 
Non-Clinical Trial Participants N=38).  Comparisons on demographic data including age, 
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household income, level of education, current employment, and access to health 
insurance and Medicaid/Medicare revealed no significant differences between groups 
with the exception of access to health insurance; fewer CT-Participants had health 
insurance.  Multiple MANOVAs performed on the MIPS-R scores revealed no significant 
differences on seven of the eight personality scales, including Introversion, Extroversion, 
Innovation-Seeking, Anxious/ Hesitating, Confident/Asserting, Submissive/Yielding, and 
Dominant/Controlling.  There were significant differences on only one scale: the 
Conservation-Seeking scale.  This indicates that people with Rheumatoid Arthritis who 
do not participate in clinical trials display a higher degree of conservatism and 
traditionalism and thus may not be willing to step outside of traditionally accepted 
medical interventions.  When comparing the Innovation-Seeking mean prevalence scores, 
neither the CT-Participants nor the NCT-Participant group approached an average score.  
Thus indicating, that while CT-Participants may exhibit less conservative and traditional 
views, it does not necessarily translate to more innovative and forward thinking when 
compared to the general population.     
Overall, scores for both the CT-Participant and the NCT-Participant groups fell 
near average on all scales, challenging previous findings that people with Rheumatoid 
Arthritis experienced higher than average rates of anxiety, introversion, and dependence.  
In fact, the NCT-Participant sample scored higher than the CT-participant group on the 
Extroverted and Confident/ Asserting scales.  This leads to questions of the validity of 
past research on the personality styles of people with RA.   
Given the small sample size for each group it is difficult to say with certainty that 
the personality styles identified in this study can be generalized to the entire rheumatic 
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population, and the population that participates in clinical drug trials.  Results may be 
further limited given the lack of a true control sample used in this study, such as a healthy 
control sample (although using prevalence scores that were normed on a healthy female 
population may provide somewhat for the comparison).  Ideally data would be gathered 
from a larger sample, possibly from multiple research sites that would provide for greater 
diversity.  The study is also limited in the generalizability of a universal personality 
profile for participants in latter phases of clinical trials, as this study only looked at 
rheumatoid arthritis.  Though there were limited significant differences noted in this 
single study, it would still be beneficial to conduct studies across multiple illnesses and 
indications to further rule out any underlying personality traits that lead one to participate 
in a clinical drug trial.   
Also important to note, research has recently focused on the lack of diversity in 
pharmaceutical trials, usually linked to distrust and a history of mistreatment (Sung, et 
al., 2003; Anderson, D., 2004).  Surprisingly, this study had seven out of forty-four 
women in the CT-Participant group who identified themselves as Native American, 
which represents a significant percentage of the total group.  The higher percentage of 
Native Americans may be attributed to study taking place in Oklahoma.  Looking at 
response data, five of the seven participants reported having access to health insurance 
and none reported receiving Medicaid/Medicare benefits.  And though information was 
not gathered on the extensiveness of health insurance coverage, these results suggest 
participation was not based on lack of medical care.  Therefore further research may be 
beneficial in understanding motivation for volunteering in typically under-represented 
populations. 
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Unfortunately the current study did not provide much insight into the motivating 
factors behind participating in a pharmaceutical research study.  As personality may be 
ruled out as one of those factors, that turns the need to explore other options.  For 
example the highest ranked motivating factor for participation in a clinical trial according 
to the demographic survey was Doctor Recommended (mean=3.50, on a scale of 1 to 5).  
What are the ethical concerns for physicians recruiting their own patients as participants 
in clinical trials where the physicians benefit financially?  On another note, ranked nearly 
as high in motivating factors, was Desire to Help Others (mean=3.39) and Desire to 
Improve Science (mean=3.34), suggesting a need to further explore altruism, chronic 
illness, and clinical trials. 
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APPENDIX A 
REVIEW OF THE LITERATURE 
CLINICAL TRIALS 
What is a Clinical Trial? 
Before any medication can be put on the market, it must undergo a series of four 
intense trials to assess both safety and efficacy of the drug, as regulated by the Food and 
Drug Administration (FDA, 2004).  These four phases of clinical trials are appropriately 
referred to as Phase I, Phase II, Phase III and Phase IV, and each serves a specific 
purpose in the process of obtaining drug approval and providing data for drug marketing 
and distribution.  During Phase I research, the drug is typically introduced to a “healthy” 
human participant.  This means that the participant has no known chronic or debilitating 
illness that could negatively interact with the medication.  Each phase, including phase I 
is usually designed as a randomized control trial (RCT) in which participant and 
researcher are blinded to dosage level of the trial drug or whether they are put on placebo. 
Researchers use this phase to assess how the drug metabolizes in the system, 
pharmacological actions, any side effects, safe dosage ranges, and early signs of efficacy 
(www.clinicaltrials.gov, 2006).  This initial stage is more focused on safety rather than on 
how well the drug works as it is introduced in the systems of otherwise healthy 
individuals, not symptomatic patients.  Phase I studies usually last a few days, and are 
often conducted in hospital settings where researchers can closely monitor the 
participants in case of any medical emergencies.  Phase I studies are conducted on a small 
sample of people, usually twenty to eighty participants scattered around the world 
(www.clinicaltrials.gov, 2006).  Once the new drug has been deemed safe for human 
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consumption, it moves onto the next phase of testing.  
Phase II clinical trials are controlled studies where the emphasis of testing moves 
from safety evaluations towards the efficacy of the new drug.  This research is conducted 
on “symptomatic” participants who display the specific indications associated with 
conditions and illnesses the medication is designed to treat.  During this phase researchers 
continue to closely assess the safety and short-term side effects of the medication even 
though it has passed the Phase I testing.  This research is usually conducted through 
hospitals, physician’s offices, and independent research centers in the United States as 
well as numerous countries worldwide.  The number of participants enrolled in this 
research is still relatively small, usually one hundred to three hundred participants per 
drug trial.  The number is kept small because the general safety is still being assessed in 
addition to efficacy, however the research is conducted using a longer timetable than was 
used in Phase I testing with ranges from days to years.  Assuming a drug is shown to be 
safe and relatively effective, it moves into Phase III testing.   
Phase III is similar to phase II with the intent of assessing overall efficacy and 
safety, but is conducted on a larger scale including more participants, usually between 
one thousand and three thousand.  Again, studies can be conducted in hospital settings, 
physician’s offices or through independent research facilities.  Phase IV trials are 
conducted once the drug has been approved by the FDA and is available to the general 
public, and are aimed at improving general knowledge of the risk-benefit ratio of drug 
usage.  During this time researchers continue to closely monitor drug efficacy and safety 
for the originally specified indications as well as for other indications. 
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Who are the Volunteers? 
According to Lemonick and Goldstein (2002) in 2001 there were 80,000 clinical 
trials conducted world wide, involving over twenty million participants.  In the United 
States most participants are Caucasian and between the ages of eighteen and sixty-five, 
though the research community has made significant efforts aimed at increasing the 
recruitment of racial and ethnic minorities (Anderson, D., 2004).  Researchers suggest the 
lack of data on ethnic minorities may be based in part on an overall mistrust of the 
researchers’ intentions (Sung, et al., 2003).  There has also been limited information on 
children and elderly, as parents may be less willing to enroll their children in trials and 
elderly may be less willing to take health risks, but data suggests the trend is changing for 
the elderly.  This may be linked to the increase in research on age-related illnesses as well 
as the rising healthcare costs for the elderly.   The typical participant has a lower socio-
economic status, earning on average 19% lower income and having less education than 
the average American.  It is assumed the prospect of free medication and free healthcare 
may attract lower SES participants (Anderson, 2004).   
A “healthy” volunteer participating in a Phase I study is typically characterized by 
age, sex, body weight, and body size. They are considered to be in good health with no 
identifiable medical conditions, which allows researchers to observe how the study 
medication reacts in the human body.  However, some research suggests that in reality 
there is no “healthy” volunteer, that instead many who participate may have some 
undiagnosed physical condition, personality disorder, or psychopathology (Lasagna, L. 
and von Felsinger, J.M., 1954).  For example Lasagna and von Felsinger (1954) reported 
that after completing a personality assessment and clinical interview, some “healthy 
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volunteers” appeared to experience severe psychosis, though authors did not expand on 
specific psychiatric illnesses the volunteers may have been experiencing.  Follow-up data 
revealed that of the fifty-five participating subjects, at least two had been previously 
hospitalized for psychiatric reasons.   Given the limited knowledge of the exact 
psychological diagnoses and the use of the poorly reliable Rorschach and psychological 
interview as the assessment tools, the findings from this study are limited in their 
generalizability.  In 1993 in a study completed by Butler et al, eighty-one ”normal” 
participants, who would typically qualify for participation in clinical trials, were given a 
series of psychological assessments including the MMPI-II, the Scale for the Assessment 
of Negative Symptoms, the Scale for the Assessment of Positive Symptoms, the Brief 
Psychiatric Rating Scales, the Hamilton Depression Rating Scale, SCL-90, Magical 
Ideation Scale, the Modified Michigan Alcoholism Screening Test, and a structured 
clinical interview to assess for psychosis and substance abuse.  Results indicated that 
fifteen participants were substance abuse likely, nineteen were psychosis prone, and eight 
were psychosis prone and substance abuse likely.  This data represents knowledge that 
pharmaceutical researchers would not have on their participants, as it is not standard 
practice to assess for mental illness or substance abuse.  Interestingly, as in the Lasagna 
study, no specific mental illness such as depression, anxiety, etc was assessed, but rather 
an overall “psychosis” rating was given.  Regardless, it is evident that there may be 
factors pharmaceutical companies are not taking into account in their drug research.  
In addition to psychopathology, researchers have also examined personality traits 
found in phase I volunteers such as emotional control and stability, assertiveness, 
sociability, flexibility, self-reliance, initiative, and impulsivity (Garcia, et al., 1998).  This 
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may be of critical importance to assess, as some pharmokenetic parameters have shown 
to be impacted by personality traits and emotional states, which will be discussed in 
greater detail further on (Claridge, G.S., Donald, J., and Birchall, P.M., 1981).  Thus 
given the possibility of biologically influencing personality traits, researchers argue in 
addition to extensive medical tests, extensive psychological testing should be conducted 
on Phase I participants, and arguably, all phases of clinical trial participants including 
symptomatic volunteers.     
A “symptomatic” volunteer possesses some medical condition that fits within the 
inclusion/exclusion criteria established in each individual trial.  For example a person 
enrolled in a Phase II study for rheumatoid arthritis would have to meet criteria for a 
diagnosis for rheumatoid arthritis.  And there are numerous studies testing rheumatoid 
arthritis medication, but each study may vary on criterion for inclusion/ exclusion such as 
disease severity, symptoms, smoking/alcohol use, etc.  As implied above, there is not the 
same call for assessing the mental health and personality profiles of symptomatic 
participants in later phases of research, so researchers have little knowledge of the type of 
person participating in phase II, III, and IV trials outside of demographic and disease 
information.  And though no explanation is given for this, one may assume there is still 
the potential for personality to impact the trial results, perhaps even more so that in phase 
I trials.  As research has shown, personality may impact one’s response to medication.  If 
there are symptomatic patients testing new drugs, they may represent a subset of those 
with chronic illness, and thus may limit the generalizability of drug efficacy.   
Potential Risks and Benefits 
There is no denying the potential risk of participating in a clinical drug trial.  
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Given the fact that most trials are set up as RCTs, participants in latter phases may be 
placed on too low a dose to be medically effective or they may be placed on a placebo.  
This potential is an obvious source of concern for those experiencing an illness (Chen, et 
al., 2003).  Being placed on a low dose or placebo could have a detrimental impact not 
only on one’s initial and continued participation in a trial, but also their morale 
considering that research has identified hope and desperation as influencing factors in 
phase II and III volunteering (Lowton, K., 2005).  It seems many participants expect they 
will receive new and “better” treatment than what has been offered in the past (Cami, J., 
et al., 1988).  Ethical consideration has also been given to the notion of exploitation, as 
many trial participants have no health insurance and come from lower socio-economic 
backgrounds (Harth, et al., 1992, National Bioethics Advisory Board, 2001).  There is 
also concern about physicians incorporating research into their private practices and the 
possibility of patient exploitation for their own financial gain (Lowton K., 2005).   
It seems researchers will constantly be forced to confront these challenges due to 
regulations established by the FDA.  Ways that researchers circumvent the perceived 
risks and ethical concerns include providing extensive informed consents on potential 
risks, opportunities to withdraw consent at any time, and safety measures for clients 
whose condition may deteriorate during the trial.  For example, if a volunteer in an 
osteoporosis study continues to experience decreased bone density during the study, they 
would be pulled from the study and given medication that is already an approved 
treatment.   
There are also benefits to participation worth mentioning.  In a 2005 an article by 
N. Herbert-Croteau et al., reported breast cancer participants enrolled in clinical drug 
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trials showed significantly lower mortality rates than those treated by standard methods, 
though the exact reasoning for this was not explored.   To researchers, this strengthens 
the belief that participating in trials may benefit people by providing the most up to date 
treatment methods.  It also calls attention to the power of belief, as improvements are 
sometimes seen in volunteers placed on placebo. Buchi, S., et al. (1997) suggests that a 
willingness to participate in a clinical trial demonstrated an ability to better adjust and 
cope with chronic illness.  This data came from a study looking at COPD patients who 
entered a trial rehabilitation program and displayed greater improvements in breathing 
and overall functioning than those receiving traditional treatment.  While some criticize 
the use of low-income volunteers who do not have medication, the reality is that clinical 
trials provide the opportunity for people to receive medical attention and cutting edge 
treatments they may otherwise have been unable to afford.  There are also the obvious 
incentives such as financial compensation and free healthcare for the duration of the 
study and often follow-up visits.  But as will be shown, there is much more to one’s 
decision to volunteer than free medication and healthcare.   
Why Volunteer? 
There have been many studies conducted over the last several years looking at the 
motivating factors for enrolling in a pharmaceutical trial when physical safety and health 
is potentially at risk (Garcia, et al., 1998, Ball, et al., 1993, Meyer, 2001, Chen, et al., 
2003).  Given the potential risks involved with volunteering it may not be surprising that 
most research as focused around why someone chooses to enroll in a Phase I trial, when 
healthy participants are asked to introduce a drug into their system that could cause at the 
minimum some form of physical discomfort or side effect, and at its worst potentially 
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lethality.  The most commonly cited motivations for participation include financial 
incentives, free healthcare and medication, altruism, scientific interest/advancement of 
science, and personality characteristics such as attraction to risky activities (Cami, J., et 
al., 1988).  Crumbo et al. (1997) cites personal and political reasons for participation in 
phase I HIV vaccine trials, with 73% of participants knowing someone who had AIDS or 
HIV.  Unfortunately research on motivating factors behind participation in phase II and 
phase III testing, particularly personality factors, just isn’t available.    
In fact Karen Lowton (2005) points out there is no real understanding of how 
people from different diagnostic patient groups respond to requests for research 
participation, which participation is obviously necessary for all phase II, III, and IV trials. 
She attempted to begin answering those questions by looking at motivating factors of 
participants with cystic fibrosis, though results were limited at best.  Thirty-one patients 
receiving treatment at a cystic fibrosis center and one hundred and eighty three other 
clinic patients were interviewed on topics such as health, quality of life, and beliefs about 
clinical trial participation.  The data was then coded and analyzed.  Her results showed 
volunteers were strongly influenced to participate by their current state of health, trial 
characteristics, and the social context.  Given this was a qualitative study, it may be 
beneficial to quantitatively assess motivations, as well as patient characteristics to aid in 
increasing researcher knowledge of phase II and III participants. 
So while many studies address participation in Phase I studies, researchers must 
start almost from the beginning when looking at the later phases.  One may almost 
assume factors such as free medication and healthcare continue to be motivating factors 
in participation in later phases, but what about the other identified factors, specifically 
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personality?  For the purposes of the current study, the research will focus on the 
influence of personality on participation in phase II and phase III clinical trials. 
Personality and Clinical Trials 
When examining data collected on Phase I volunteers, there is consensus that 
several factors influence one’s decision to participate, including personality (Meyer, 
2001).  Personality traits identified in phase I participants typically include emotional 
control and stability, assertiveness, sociability, flexibility, self-reliance, initiative, and 
impulsivity (Garcia, et al., 1998, Ball, et al., 1993, Cami, et al., 1988).  Cami, et al 
(1988), found elevated scores of extroversion and psychoticism as assessed by the 
Eysenck Personality Questionnaire (EPQ) in sixty-two male phase I volunteers.  Results 
were compared to a control sample of ninety-six male college students who had similar 
sociocultural characteristics.  Researchers infer the elevated psychoticism and 
extroversion suggests greater impulsivity and sociability, which could be used as 
predicting factors of clinical research participation.  In contrast, Ball, C.J., et al (1993) 
assessed the personality structure of sixty-five phase I volunteers using the Eysenck 
Personality Questionnaire, in which results showed a pattern of increased extroversion, 
and decreased neuroticism and psychoticism.  Ball, et al suggests the significantly low 
neuroticism and high extroversion may cause a higher threshold for thrill sensation, 
which may influence participation in clinical research and other potentially dangerous 
behaviors.  These results were also present in a study by Eysenck and Eysenck (1975) in 
which healthy volunteers also demonstrated high extroversion and low neuroticism and 
psychoticism when given the EPQ.  While the EPQ is a valid and reliable assessment, the 
research may be lacking given the limited information available, suggesting a more 
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comprehensive assessment such as the MIPS, 16PF and MMPI could be useful as 
researchers continue to expand their knowledge of clinical volunteers.    
Again, the research is unavailable for participants in Phase II and III studies, with 
no discussion on why researchers see this to be of little importance.  Only one study was 
located where research looked for presence of psychopathology and personality disorders 
in Phase II and III trials, but not overall personality traits (Barrett, J., 1981).  In this case 
participants were found to have higher degrees of psychological issues including 
depression and anxiety than was accounted for in the clinical trial descriptions.  For 
example instead of diagnosing depression, a participant was described as having some 
depressive symptoms, which did not give a clear picture of what those were.  Authors 
argue diagnoses should be clear and explicit to aid in the generalizability of drug efficacy 
information.   
Why would this information be important for researchers to know, especially 
those conducting clinical trials on new medications?  One reason is that personality has 
repeatedly been shown to impact the absorption, biotransformation, and other 
pharmokenetic parameters of several medications (Tishler et al., 2003, Meyer, F.P., 
2001).  These include but are not limited to diazepam, caffeine, paracetamol, and 
theophylline (Meyer, F.P., 2001).  Psychological and personality factors that have been 
shown to influence drug absorption include but are not limited to 
introversion/extroversion, levels of anxiety, and success/failure motivation.  For example, 
extroversion and neuroticism are associated with high barbiturate threshold, and 
neuroticism is linked to high diazepam absorption (Claridge, G.S., Donald, J., and 
Birchall, P.M., 1981).  However, Garcia et al. (1998) suggests the influence of 
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personality may not be as powerful as once believed, following a study analyzing 
emotional reactivity, performance, and vigilance in anxious and non-anxious volunteers.  
Researchers saw an increase in emotional reactivity, but no difference in performance 
and vigilance following emotional induction.  The researchers inferred that personality 
might not be necessary to assess prior to research involvement, as it may not influence 
medication efficacy results.  While researchers acknowledge this is a big conclusion to 
reach, it seems more research is needed in the area of personality/psychopathology and 
drug interaction. 
Researchers also suggest that personality characteristics influence the reporting 
styles of the participants, not just the pharmokenetic parameters (Ball, C.J., McLaren, 
P.M., and Morrison, P.J., 1993).  They suggest that personality traits may impact the 
frequency of reported side effects.   Meyer (2001) reported that participants who scored 
high on anxiety scales had more complaints of side effects due to study medication, 
whereas participants who expressed less nervousness, emotional stability, and high 
motivation had fewer complaints.  These reasons have influenced researchers to 
categorize more based on personality characteristics, motivation, and emotional state, but 
only in Phase I studies.  It seems that researchers should especially be interested in 
obtaining personality information from phase II, III, and IV participants, given that 
personality has long been associated with the onset and progression of chronic illness. 
The Future of Clinical Research 
 There is no denying the plethora of information available on Phase I research and 
participants, but there is an obvious lack of data on Phase II-IV participants.  Possible 
explanations may be an assumption that the medication and healthcare are the obvious 
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motivators behind participation.  Researchers may also ignore latter phases of clinical 
trials because they do not appear to carry the same risk potential as participation in a 
phase I study.  However, safety is continually assessed with every phase, with the latter 
phases having the added goal of testing efficacy.  There appears to be growing awareness 
that there are inconsistencies between personality characteristics found in research 
participants, and those found in people with chronic illness, i.e. Lowton’s study on cystic 
fibrosis (1995).  If one looks to research on specific illnesses, the need to assessment 
becomes even more apparent.  For example people with Rheumatoid Arthritis and other 
chronic illnesses are often reported as being depressed, anxious, and dependent, a far cry 
from the extroverted low-neurotic profile of a phase I volunteer.  Meyers (2001) calls 
attention to the fact that drugs will be used on people with complete opposite 
characteristics than phase I participants as reason to assess personality on phase I 
participants, yet fails to connect this to a need to assess personality in phase II studies.  I 
argue that personality and other motivating factors influencing participation in Phase II 
and III are just as important as they are in Phase I, if not more so, as companies should 
gather data on the exact population they are trying to find cures for.  Especially when 
considering the data that suggests personality influences drug action, pharmaceutical 
companies should look at all volunteers to improve drug knowledge, external validity, as 
well as recruitment strategies.   
This may seem a challenging and daunting task, as it would involve researchers 
gathering personality information on every patient group, so this study will start with one: 
Rheumatoid Arthritis.  Specifically this study will examine the personality characteristics 
of rheumatoid arthritic patients in phase II and phase III clinical trials, and the role 
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personality may play in one’s decision to participate. 
RHEUMATOID ARTHRITIS 
What is Rheumatoid Arthritis? 
Rheumatoid Arthritis (RA) is disease that causes inflammation of the joints that is 
not associated with injury or wear, as is osteoarthritis. Studies show that RA is the 
number one cause of disability in the United States, with nearly forty million people 
experiencing some form or symptom of arthritis (Mayo Clinic on Arthritis, 2002).  These 
numbers have made finding a cure a priority for research institutions and pharmaceutical 
companies, which has proven very challenging, as there is currently no known cause or 
cure-all for rheumatoid arthritis.   
Though the exact cause of the disease is unknown, it has been shown to have a 
genetic link and may be connected to an abnormal immune system.  RA is thought to be 
an autoimmune disease in which the body starts attacking itself; specifically, antibodies 
attack the lining of the joints.  The American Rheumatism Association established seven 
diagnostic criteria for rheumatoid arthritis, of which one must satisfy at least four or five 
for a definite diagnosis, and six to seven for a classical diagnosis (Arnett, F., et al, 1988).  
Those criteria include: morning stiffness, arthritis of three or more joint areas, arthritis of 
hand joints, symmetrical soft tissue joint swelling, subcutaneous rheumatoid nodules, 
radiographic changes to bones or joints, or a positive serum rheumatoid factor. Symptoms 
can also include pain and swelling in the joints of the hands, feet, wrists and ankles; aches 
and stiffness of joints and muscles; decreased mobility in diseased joints; deformity of 
affected joints; fatigue; nodules on hands, feet, elbows, knees and the scalp.  The 
symptoms are generally chronic, but can come and go and vary in intensity over the 
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course of the disease.  RA typically begins between the ages of 20-50, though can be 
present in children (referred to as juvenile arthritis).  Diagnosticians classify patients 
according to stages, or disease progression, and classes, which describes the level of 
functional incapacity.  Those classes are broken into four divisions: class 1- no functional 
impairment in daily living tasks; class 2- able to adequately function in normal life with 
minor impairment; class 3- limited function, but still able to engage in daily living tasks; 
class 4- unable to function independently.     
There are many identified factors that influence the onset and progression of the 
disease including the environment, viruses, bacteria, fungi, gender, an imbalance of 
enzymes, stress/emotional trauma, and the focus of the current study, personality factors 
(Mayo Clinic, 2002).  Cobb, B. et al., (1969) concluded that people with certain 
psychological characteristics, when exposed to the right environmental factors, will 
display physiologic responses associated with certain illnesses, i.e. rheumatoid arthritis.  
Oberai and Kirwan (1988) agree that pre-morbid personality may play a role in the 
development of RA, as unconscious or habitual patterns of coping may reflect a tendency 
to deny emotions and thus those individuals are more prone to somatic complaints.   
Some researchers argue there is no concrete way to determine if there are personality 
traits present before the onset of the illness, and therefore causality data should be 
considered inconclusive (Moos and Solomon, 1965; Anderson, et al, 1985).  This 
considered, there is much agreement that personality plays a role in the course of illness 
and treatment efficacy.      
Personality and Rheumatoid Arthritis 
Research is lacking in the area of causality or whether there is a “rheumatoid 
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personality” that predisposes someone to the illness.  The question still remains if these 
personality traits were present prior to the onset of rheumatoid arthritis or if they are a 
result of a painful and often disabling disease.  Therefore research conducted looking at 
personality profiles of arthritics should be used with caution.  Data may also be flawed 
based on sampling errors, assessment selection, etc (Nalven, F.B and O’Brien, J.F., 1968, 
Moos and Solomon, 1966, Anderson et al, 1985).  Much of the data on personality and 
arthritis is dated backing the fifties, with research conducted from several theoretical 
approaches ranging from psychoanalytic to behaviorally focused, but mostly relying on 
heavily psychoanalytical assessment.  For example several researchers relied on 
assessments such as the Rorschach or psychoanalysis, in which results may have been 
influenced by subjective interpretations.  Others have taken fully validated and reputable 
assessments such as the MMPI and created their own assessment tools, which decreased 
validity, reliability, and generalizability.  Many studies also used instruments such as the 
MMPI, which are better suited to assess psychopathology, not normal personality 
characteristics.  In fact there is little differentiation within the literature between state/trait 
personality factors, and psychopathology.   
Studies in the past have had difficulty determining control variables to represent 
the closest match to the experimental sample in studies of psychosomatic illnesses such 
as rheumatoid arthritis and hypertension (Hardyck and Moos, 1966).  They suggest that 
even with control groups, researchers will find widely differing personality 
characteristics.  Rarely are rheumatic participants compared to other chronic illness 
groups or other rheumatic groups, and the use of otherwise healthy people as control 
groups may influence finding significant results.  Researchers suggest that there is no 
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specific match that can truly account for familial, socioeconomic, age, gender, 
educational, and other environmental differences that have been identified as influential 
in the course of illness in arthritic patients, though unfortunately that is a flaw common in 
most research.  Therefore research studies designed to establish personality profiles 
specifically in psychosomatic patient samples are potentially obsolete.  Some researchers 
have chosen to compare family members, as they share the closest match in 
psychological and sociological factors that have been linked to the onset and progression 
of rheumatoid arthritis.  Others have attempted to match on disease severity and course of 
illness, which is what is proposed for the current study, as control and experimental group 
will match on disease severity and functional mobility.  Research complications aside, 
there is a plethora of important research on personality and rheumatoid arthritis of which 
the following details: 
Dating back to 1909, the relationship between personality and rheumatoid arthritis 
has been well researched, though the exact nature of this relationship still is not clear 
(Moos, H.D., and Solomon, G.F., 1964; Robinson, et al., 1972; Hardyck, C., and Moos, 
H.D., 1966; Moos, H.D., and Solomon, G.F., 1965).  For example, many have tried to 
establish a “rheumatoid personality” that may suggest a predisposition to the illness.  
Those personality traits linked with rheumatoid arthritis have included subservience, 
nervousness, restlessness, depression, conservatism, and hypersensitivity to anger (Moos 
and Solomon, 1964).  There is significant debate about whether or not personality traits 
associated with rheumatoid arthritis were present prior to or after disease onset, which 
unfortunately may never be known, as it would be near impossible to predict who will 
later develop the disease and thus provide opportunities to assess personality prior and 
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following disease onset.  There is also significant debate about what those personality 
traits found in people with rheumatoid arthritis are, and how those results were 
determined.  For example much of the research out there dates back to before 1970, and 
assessments relied heavily on projective measurements and investigator inferences.  In an 
article reviewing rheumatoid arthritis/personality research written by Rudolph Moos 
(1964) it was stated that much of the research conducted before 1963 did not include the 
use of control subjects, as well as utilized a very strong psychoanalytic approach to study 
design and interpretation.  Overall common results included a tendency to over-
somaticize and reflect personality traits such as rigidity and conformity.  Though 
researchers all had similar findings, results can only be generalized so far without proper 
control and design.   Others still argue that there is in fact no “rheumatoid personality,” 
but rather a “chronic illness personality” that develops following the onset of any illness.  
Anderson et al (1985) describes the chronic illness personality as depressed and neurotic.  
In a 1988 study by Antonio Puente comparing MMPI scores of chronic arthritics to 
chronic pain patients similar in SES, educational level and sex, no significant differences 
in personality profiles were detected.  This study is limited by the low number of 
participants (twenty-two in each control and experimental group).  It is also limited by 
the use of the MMPI that, while widely used as a personality assessment, emphasizes 
more psychopathology and less personality description.  These obvious discrepancies 
necessitate further exploration into the research to explore critical errors that may 
compromise earlier findings and conclusions regarding the nature of the relationship 
between personality and rheumatoid arthritis.  
Moos and Solomon conducted several studies in the 1960’s as part of a 
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longitudinal study looking at rheumatoid arthritis and personality factors.  One such study 
compared personalities of sixteen arthritic patients to their closest-aged, same-sexed, 
healthy, non-arthritic siblings (1965).  The researchers saw this as an opportunity to 
control for influential background factors including age, sex, and parent’s occupational 
status.  Moos and Solomon assessed specific personality traits including dependency, 
physical activity, masochism, nervousness, and depression through the use of the 
Minnesota Multiphasic Personality Inventory (MMPI), a semi-structured interview, and a 
specially constructed personality test the incorporated results from previous research in 
the field of personality and rheumatoid arthritis.  Results from the MMPI and the devised 
assessment showed significant differences on the compliance/subservient, 
nervous/restless, depression, conservatism/security, and sensitivity to anger scales. 
Contradicting previous research, Moos and Solomon did not find significant differences 
in dependency, interest in physical activity, or duty-orientation and conscientiousness.  
There were no significant findings supported by all three assessments.   
Looking at this study from a critical standpoint, several factors appear to impact 
the validity of this study.  First, scales were rationally derived from the MMPI, which 
may negatively impact the validity, reliability, and generalizability of the results.  As the 
researchers themselves pointed out, there were no statistical analyses conducted between 
assessments, which may have strengthened or weakened their findings. A glaring 
limitation to this study is the lack of subjects, with only 16 sibling pairs providing data, 
all of who were women.  Interestingly, results from medical exams required for 
participation revealed several of the “healthy” siblings had characteristics associated with 
latent rheumatoid arthritis, which was not included as a control factor.  It appears that 
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researchers did not see this as a necessary control variable as they did not present with 
somatic complaints as the rheumatic siblings did.  However, this may be an important 
variable to consider, as part of the underlying research goal of their longitudinal research 
is to determine the exact relationship between personality and rheumatoid arthritis (i.e. 
causality, onset, impact on disease progression).  
 Taking the results from this study, Moos and Solomon (1964) attempted to 
generalize their findings to a larger experimental group.  In this study forty-nine female 
rheumatic patients and fifty-three of their “healthy” female family members completed 
the MMPI.  As in the previous study, eleven scales were rationally derived from specific 
questions on the MMPI.  In this study however, the nine clinical scales and three 
validation scales were also used.  Results showed the rheumatic siblings were elevated on 
the hypochondriasis, depression, and hysteria scales.  These results appear to match data 
collected on chronic illness suffers, suggesting rheumatoid arthritics share similar 
experiences such as over-somatization, self-sacrifice, masochism, rigidity, conformance, 
and perfectionism (Cohen, 1949).  Moos and Solomon infer that emotional suppression, 
especially suppression of anger, may lead to muscle tension and thus increased joint 
pressure, pain, and joint damage, linking personality with the onset and progression of the 
disease.  While this study increased the number of participants, it is still hampered, as in 
the previous study, by the presence of latent rheumatic symptoms in the “healthy” 
volunteers.  The results are also limited by the use of only female participants as well as 
the questionable validity of the derived MMPI scales.  This study does, however, present 
with solid quantifiable results from a valid assessment that reflects a difference in 
personality traits between rheumatic patients and a healthy control sample.  Moos 
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previously critiqued researchers’ failure to assess and incorporate socio-economic status 
information into research.  While parent’s occupational status and age were assessed, no 
statistical analyses were conducted to explore the impact these factors may have on 
results.  And while these two articles represent data obtained from long-term studies, no 
chronological data was collected from participant groups over a long period of time.  
Some may argue that this may not be necessary as personality traits are inherent and 
therefore consistent across time, but there is no research that supports this throughout the 
course of this chronic and often debilitating illness. 
Personality and the Course of Illness 
Though the exact mechanisms are unclear, it is accepted that personality factors in 
addition to biomedical factors have long-term effects on the course of illness.  Robinson, 
et al (1972) sought to clarify the relationship between personality and disease progression 
in a study comparing forty-one chronically ill patients with rheumatoid arthritis, 
osteoarthritis, and other non-arthritic chronic pain illnesses.  Robinson and colleagues 
questioned the role of personality and disease progression in rheumatoid arthritis 
compared to other non-arthritic chronic pain illnesses to determine if personality 
characteristics such as anxiety and depression evolve over time as illnesses progress.  The 
chronically ill participants were identified as new arthritis (NRA), old arthritis (ORA), 
and new pain or old pain patients.  The goal of the study was to identify personality 
factors associated with various stages of arthritis, and whether these factors are associated 
only with arthritis and therefore contribute to disease onset and progression, or whether 
results represent personality patterns seen in the onset of other chronic pain illnesses and 
therefore represent a generic chronic illness pattern of personality responses.  Personality 
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traits were assessed using Cattell’s 16PF, as well as the Eysenck Personality Inventory 
(EPI).  Results showed near statistical significance on overall differences between NRA 
and ORA.  This contradicted the author’s hypothesis, which was that NRA and ORA 
scores would be highly similar.  NRA and other pain groups exhibited greater anxiety 
scores.  The authors suggest this does not reflect a consistent personality profile for RA 
patients, but rather a pattern of variability on single scales (for example overly 
suppressing anger or overly expressing anger).  Statistically the results are not strong 
given the lack of participants, with an average of ten participants per group.  However 
this study does suggest the need to further explore the relationship of rheumatoid arthritis 
to other chronic illnesses, particularly in the popular field of personality research.   
In much of their research, Moos et al., (1963, 1964,1965) also sought to establish 
the relationship between personality factors and the course of illness. When controlling 
for stage of illness, researchers saw differences in functional capacity, which they 
attribute to personality differences (Moos, R.H. and Solomon, G.F., 1964).  Participants 
who displayed poor functioning displayed greater introversion, depression, social 
isolation, anxiety, anger, fear, and insufficient coping skills, while higher functioning 
individuals displayed more extroversion, greater coping skills, etc.  Moos and Solomon 
also hypothesized that “negative” personality traits could be potentially harmful, as they 
may intensify the crippling effects of rheumatoid arthritis.  They determined that anxiety 
and neuroticism might increase risk of arthritic flares or increase joint pain and stiffness, 
fatigue, and swelling (Moos, 1964).  In one study forty-nine arthritic women were 
classified by stage of disease progression (one through four with one being early stage 
and four being late stage RA), and class of functional incapacity (with one being little 
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incapacitation to four being very incapacitated) (Moos, R.H. and Solomon, G.F., 1964).  
From this group two subgroups were picked for study participation.  These groups 
consisted of women whose degree of functional incapacity was higher than disease 
progression (n=11) and a second group of participants who presented with greater disease 
progression than functional incapacitation (n=18).  The researchers attempted to match 
for disease progression and duration of illness, but were not successful given the limited 
number of participants.  Each group was then given a demographic questionnaire and the 
MMPI.  The demographic questionnaire allowed researchers to control for age, 
education, marital status, number of children and occupational class.  The MMPI 
analyses included rationally derived scales used in their previous research (Moos and 
Solomon, 1964; Moos et al 1963). Using T-tests to compare results of the two groups 
responses showed 32.9% significance at the 0.01 level, indicating a there were 
significantly different response patterns between the two groups.  Results showed that 
participants who were functioning below their disease stage would exhibit acute distress 
and an inability to cope.  Results also suggest they experience greater shyness, 
introversion, alienation, and decreased social participation.  The group that functioned 
equal to or better than their disease stage would suggest exhibited less depression and 
apathy, and greater motivation.   
From this study researchers hypothesized that successful rehabilitation could be 
determined by psychological characteristics prior to the beginning of rehabilitation.  
Therefore successful rehabilitation may also require psychological interventions to help 
overcome the personality traits that may interfere.  According to Moos and Solomon, 
these findings may also suggest rheumatoid arthritics are not a homogeneous group, and 
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therefore may not present with a solid personality profile from which to make 
comparisons of the group as a whole.  They also suggest the importance of controlling for 
stage, class, and duration of illness when conducting personality studies.  Critically this 
study is discredited some by the size of the sample groups (n=11, n=18).  The statistical 
analysis is questionable considering the use of rationally derived scales instead of the 
validated MMPI scales.  While the researchers assessed age, education, etc., no analyses 
represented these differences.  However, this article adds credence the question of 
whether people with chronic illnesses participate in clinical trials out of desperation or 
whether they represent a subgroup within RA of people who are better able to function as 
they are willing to look outside the box of traditional and established treatment.    
Langley, et al (1983) conducted a study examining the effects of placebo therapy 
in rheumatoid arthritis and found that rheumatic patients experiencing anxiety are more 
prone to pain, yet respond more positively to placebo.  In this study pain was assessed 
daily for twenty-five days in twenty-three participants with rheumatoid arthritis.  All 
participants were given a placebo the last nine days, with the first sixteen days serving as 
a baseline pain provider.   The Eysenck Personality Inventory was completed prior the 
beginning of the study.  Results show that introverted participants showed no change in 
pain response (i.e. did not report improvements or decline in pain).  Neuroticism was 
higher in participants who reported side effects.   The study is obviously limited by the 
low number of participants (final n=18), but findings still pose an interesting question 
about the role of anxiety in medical treatment.  In this study, high neuroticism scores 
were reflected in those who reported negative side effects, and those who reported 
improvement.   This has several implications for the medical field in addition to the 
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pharmaceutical research field, as personality may influence drug response data.   
Personality also impacts the course of illness in such a way that if a person 
experiences high anxiety and fear, they may be less likely to engage in physical activity 
for fear of pain or permanent damage.  The lack of physical activity actually leads to 
greater impaired functioning. Brooks and McFarlane (1983) also found that 
psychological factors predicted more variance in disability than disease activity.  And 
while the personality traits do not directly cause functional decline, evidence suggests 
they may impact one’s response to medication.  McLaughlin, et al (1953) states that 
personality differences in arthritic patients impacted patients’ responses to a number of 
different medications, but particularly ACTH.  In an exploratory study looking at men 
and women diagnosed with RA, stress and anxiety were found to negate any positive 
reaction to treatment.  Limitations to this study include the limitations in assessment and 
diagnosis of personality/psychological traits, suggesting the study should be replicated 
using modern assessment and treatment interventions.     
Latman and Walls (1996) established a relationship between stress and the onset 
of rheumatoid arthritis.  In this study 128 participants diagnosed with classical or definite 
arthritis and 79 participants diagnosed with osteoarthritis were asked to complete 
Cattell’s 16PF and the Social Readjustment Scale of Holmes and Rahe which assesses 
any stressful life events at the age of disease onset.  Examples of stressful events include 
loss of a family member or spouse, marital discord, problems at work, financial troubles, 
pregnancy, illness, and interpersonal conflicts (Booth, 1937).  Results showed that RA 
patients experienced greater stress at the time of disease onset.  And though a causal 
relationship was not established, participants with rheumatoid arthritis experienced 
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stressful events at the time of disease onset tended to display greater disease and 
symptom severity as opposed to participants with osteoarthritis.   There was no statistical 
difference between personality scores between RA and OA, however RA participants 
tended to exhibit greater anxiety and seriousness.  This may reflect the relationship 
between anxiety/neurosis and disease progression, as one may be more susceptible to 
anxiety during difficult life events.  This study may have erred by not using a healthy 
control group, as OA can be pain and debilitating just as RA.  However, it is possible that 
type of data may lend credit to the chronic illness personality hypothesis versus the 
rheumatoid personality.   
Lowman, E.W., et al (1954) showed that personality factors leading to successful 
RA rehabilitation included independence, a realistic outlook, emotional control, and 
pleasure seeking behaviors.  This suggests that treatment and rehabilitation success could 
be predicted by personality traits, and has led to an increase in research studying the 
impact of psychotherapy in treatment, which has shown great success (Bradley, et al., 
1987). In a study looking at 53 patients with RA, pain, anxiety, and disease activity were 
reduced when treatment included psychotherapy.  
CLINICAL TRIALS AND RHEUMATOID ARTHRITIS 
As the research suggests, there is debate about whether or not a rheumatoid 
personality exists.  There is substantial evidence, however, that suggests the personality 
styles play a role in disease onset and progression.  Given the role personality plays in 
disease progression, it is not a stretch to question whether there are there similar 
personality characteristics at work that influence one to seek alternative treatments such 
as participating in clinical trials.  So the presenting question is: how do personality styles 
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in participants in rheumatoid arthritis clinical trials compare against personality features 
in those who do not participate in clinical trials?  Are personality styles of participants 
reflective of the extroverted, independent Phase I volunteer, or do the styles match those 
commonly seen in chronically ill arthritic patients?  Participating in a trial may be seen as 
a willingness to explore alternative options, an openness to new experiences, which is in 
line with the research conducted on stage I participants that suggests an openness to new 
experiences, low anxiety, and independence.  However coping with a chronic illness has 
been shown to negatively impact personality and psychopathology.  The personality of a 
rheumatic clinical trial participant could skew the drug efficacy data, as higher anxiety 
and introversion are linked to greater somatic complaints as well as biomedical drug 
interactions.    
It is also important to consider the impact of SES, as Koster, et al. (2004) 
associated low SES and low education with functional mobility decline and physical 
disabilities in the chronically ill, including rheumatoid arthritis.  Data reports that 
participants in clinical trials typically come from lower SES.  The pharmaceutical 
companies do not appear to control for SES when running trials, just as they do not 
control for personality traits.  To answer these and other questions there appears to be no 
doubt of the importance for researchers to assess personality in all phases of clinical 
trials, not just phase I. Therefore it is the purpose of the present study to examine 
personality characteristics of rheumatoid arthritic participants in phase II and phase III 
clinical trials.  In addition, the present study will account for variables including socio-
economic status, education, motivation for participation in the clinical trial, gender, and 
race.  Despite the lack of information in this area, it is hypothesized that personality 
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profiles of rheumatoid arthritics who participate in later phase clinical trials will more 
closely resemble those of phase I participants than that of a typical arthritic.  Specifically 
it is hypothesized clinical trial participants will display greater extroversion, openness to 
new experiences, independence, and less anxiety.  If this hypothesis is accurate, the 
implications for pharmaceutical research could be tremendous, as it research has already 
shown personality may impact how drugs react in the body.  If there is a specific 
personality type that engages in pharmaceutical research, all medical data may be skewed 
or inaccurate, as the results would not reflect how medication reacts in the general 
population.   
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APPENDIX B 
Demographic Questionnaire 
Please circle the answer that best fits you: 
1.  Age :_____ 
2.  Annual Household Income:  A. Under $15,000   B. $15,000-30,000    C. $30,000-
45,000   D. $45,000-60,000 E. $60,000+ 
3.  Highest Level of Education: 
 A. Did not complete high school    B. High school/GED C. Some college/technical  
 D. College/Technical Degree  E. Graduate School 
4.  Race/Ethnicity: 
  A. Caucasian   B. African American    C. Hispanic/Latino   D. Asian/Pacific Islander 
 E.  Native American   F.  Other: _________________________ 
5.  Do you have health insurance?  A.  Yes B. No 
6.  Are you currently employed?  A.  Yes B. No 
7.  Do you receive Medicaid/Medicare?  A.  Yes  B. No 
8. Have you ever participated in a pharmaceutical trial not related to Rheumatoid Arthritis?    
  Yes     No If yes, please describe what for: _______________________ 
 
9. If you answered yes to #8 or if you are currently enrolled in a clinical trial for rheumatoid 
arthritis, please answer the following question.  Provided below are commonly reported 
reasons for participating in clinical trials.  Please rank on a scale from 1 to 5 how these 
factors influenced your decision to participate in a clinical trial.  
    Strongly Disagree     Disagree   Neutral   Agree     Strongly Agree  
A.  Free healthcare/medication  1  2 3             4  5 
B.  To help others   1  2             3            4  5 
C.  To improve science   1  2  3            4  5 
D.  Financial compensation  1  2  3            4  5  
E.  My doctor recommended it  1  2  3  4  5 
F.  Previous treatment was not effective 1  2  3            4  5 
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APPENDIX C 
 
Understanding Personality Styles of Participants in Phase II and III Rheumatoid 
Arthritis Clinical Trials  
 
INFORMED CONSENT 
In this study the researcher, Elisabeth Riccardi, is looking at personality characteristics of 
people with Rheumatoid Arthritis who choose to participate in Phase II and Phase III 
clinical drug trials.  Elisabeth, a doctoral student in the counseling psychology program, 
is conducting the project through Oklahoma State University.  Participants will be asked 
to fill out two documents.  One is a demographic questionnaire; the other is the Millon 
Inventory of Personality Styles Revised (MIPS), a general personality inventory.  This 
should take no more than 45 minutes to complete.  No identifying information will be 
requested, so confidentiality of responses will be protected.   
The records of this study will be kept confidential. Research records will be stored 
securely here onsite, and only researchers and individuals responsible for research 
oversight will have access to the records. It is possible that the consent process and data 
collection will be observed by research oversight staff responsible for safeguarding the 
rights and well-being of people who participate in research. Once all surveys are 
completed, the researcher will collect the records.  At that time the records will continue 
to be kept in a locked cabinet under the researcher’s care while the data is recorded and 
analyzed.  Once analysis in complete, all records will be shredded and disposed of 
properly so as to continue to protect confidentiality.  Any written results will discuss 
group findings and will not include information that will identify you.  
There are no foreseeable discomforts that will arise from participating in the study, 
however if this occurs, it is recommended that you seek the help of a mental health 
professional.  There is no obligation to participate in this study, but if you choose to 
participate, you have the opportunity to enter a drawing for one of four $25 dollar gift 
certificates.  If you choose to enter your name for the drawing, the name will be kept 
separate from the responses, thus still maintaining confidentiality.   
If you have any questions regarding your participation in this study, please contact 
Elisabeth Riccardi at Elisabeth.Riccardi@gmail.com, or her advisor, Don Boswell, PhD., 
at don.boswell@okstate.edu.  If you have questions about the research and your rights as 
a research volunteer, you may also contact Dr. Shelia Kennison, IRB Chair, 219 Cordell 
North, Stillwater, OK 74078, 405-744-1676 or irb@okstate.edu. 
 
I have read and fully understand the consent form.  I sign it freely and voluntarily.  A  
copy of this form has been given to me. 
________________________                  _______________ 
Signature of Participant   Date 
 
I certify that I have personally explained this document before requesting that the  
participant sign it. 
________________________         _______________ 
Project Director or authorized representative   Date 
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APPENDIX D 
 
 
Solicitation Script 
 
 
 
Hello.  A counseling student from Oklahoma State University, Elisabeth Riccardi, is 
conducting a study here at our office as part of her doctoral training.  She is studying 
personality styles in patients with rheumatoid arthritis and patients who participate in clinical 
drug trials, and is looking for participants to complete a one-time only survey study.  
Participation is completely voluntary, and if you would like to participate, you will be asked to 
read and sign an informed consent and then complete a brief demographic survey and 
personality survey.  All information will be kept confidential, and the entire process should 
take no more than 30-45 minutes to complete.  If you choose to participate you also may enter 
your name into a drawing for one of four $25 gift certificates, which will be drawn once all 
data in collected, probably in July or August.  Again, you are not required to participate; this is 
completely voluntary.  Would you be interested in filling out the surveys today?       
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Participants) were asked to complete a demographic questionnaire and the Millon 
Index of Personality Styles-Revised (MIPS-R).  The MIPS-R was used to measure 
the presence of personality traits identified as contributing factors to participation 
in Phase I trials including: openness to new experiences, low anxiety, 
extroversion, and independence.  The demographic questionnaire assessed age, 
race/ethnicity, annual household income, level of education, and access to 
healthcare, Medicaid, and Medicare.   
 
Findings and Conclusions:  Demographically the two groups were statistically matched 
on age, level of education, annual household income, and access to 
Medicaid/Medicare.  The two groups differed significantly on access to health 
insurance.  There was a significant difference between the two groups on the 
Conservation-Seeking scale indicating a tendency for the NCT-Participant group 
to exhibit more traditional and conservative behaviors, and thus less open to new 
experiences.  The CT-Participants and NCT-Participants matched on all other 
scales including Introversion/Extroversion, Submissive/Yielding, Innovation-
Seeking, and Anxious/Hesitating, Confident/Asserting, and Dominant/Controlling 
scales, indicating those who participate in clinical drug trials share personality 
traits commonly associated with Rheumatoid Arthritis. 
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